Subscribe
shutterstock_1524542537_michael_vi
Michael Vi / Shutterstock.com
24 August 2021MedtechAlex Baldwin

Fed Circ upholds challenge to J&J robot patent

The US Court of Appeals for the Federal Circuit has invalidated more claims of a Johnson & Johnson (J&J) subsidiary’s surgical robot patent following a cross-appeal of a Patent Trial and Appeal Board (PTAB) decision.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
J&J units launch prostate cancer drug suit
31 May 2022   Johnson & Johnson subsidiaries Aragon Pharmaceuticals and Janssen Biotech have sued three pharma companies for alleged infringement of five patents relating to prostate cancer treatment Erleada.
Medtech
Fed Circuit revives bid to invalidate robotic surgery patent
3 May 2022   The US Court of Appeals for the Federal Circuit has renewed Auris Health’s attempt to invalidate Intuitive Surgical’s patent covering a robotic surgical tool.
Medtech
Fed Circ denies bid to reverse favourable J&J ruling
15 February 2022   The US Court of Appeals for the Federal Circuit has affirmed two Patent Trial and Appeal Board rulings that a Johnson & Johnson subsidiary’s patent is valid and infringed.


Editor's picks

Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025

Editor's picks

Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025

More on this story

Americas
J&J units launch prostate cancer drug suit
31 May 2022   Johnson & Johnson subsidiaries Aragon Pharmaceuticals and Janssen Biotech have sued three pharma companies for alleged infringement of five patents relating to prostate cancer treatment Erleada.
Medtech
Fed Circuit revives bid to invalidate robotic surgery patent
3 May 2022   The US Court of Appeals for the Federal Circuit has renewed Auris Health’s attempt to invalidate Intuitive Surgical’s patent covering a robotic surgical tool.
Medtech
Fed Circ denies bid to reverse favourable J&J ruling
15 February 2022   The US Court of Appeals for the Federal Circuit has affirmed two Patent Trial and Appeal Board rulings that a Johnson & Johnson subsidiary’s patent is valid and infringed.

More on this story

Americas
J&J units launch prostate cancer drug suit
31 May 2022   Johnson & Johnson subsidiaries Aragon Pharmaceuticals and Janssen Biotech have sued three pharma companies for alleged infringement of five patents relating to prostate cancer treatment Erleada.
Medtech
Fed Circuit revives bid to invalidate robotic surgery patent
3 May 2022   The US Court of Appeals for the Federal Circuit has renewed Auris Health’s attempt to invalidate Intuitive Surgical’s patent covering a robotic surgical tool.
Medtech
Fed Circ denies bid to reverse favourable J&J ruling
15 February 2022   The US Court of Appeals for the Federal Circuit has affirmed two Patent Trial and Appeal Board rulings that a Johnson & Johnson subsidiary’s patent is valid and infringed.

More features

Fed Circ: Generic doesn’t infringe Metacel MS drug
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
Strategic IP protection for biotech-related GenAI
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart Bradley on 9/11, inclusion and the INTA presidency
Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress